On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...

As Lina Khan, chair of the Federal Trade Commission, ends her tenure this week the FTC posted a second report in six months ...

Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...

At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

Pharmacy Benefit Managers (PBM) sit in the center of our prescription drug system, coordinating between insurance companies, ...

Shocking revelations from a Federal Trade Commission, or FTC, investigation have exposed how three major prescription benefit managers, or PBMs, ...

The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...

"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...

The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

In the report, the FTC said pharmacy benefit managers (PBMs), charge significant markups for cancer, HIV, and other critical ...

FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...